News from Zyme and the companies we work with.
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies
Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services Immunome signs deal to use Arrayjet platform in its in-house screening operations [...]
Nuclera appoints Joseph Bertelsen as Chief Commercial Officer
Key appointment to lead global commercial launch of eProtein Discovery platform Cambridge, UK, 14 March 2024: Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its benchtop [...]
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model Tokyo, Japan, and Dublin, Ireland, March 13, 2024: Ricoh Company, Ltd. today announced a non-exclusive [...]
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study Cambridgeshire and Belfast, UK, 12 March 2024: Exploristics, a [...]
Metrion Biosciences strengthens team with three key appointments
Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer Cambridge, UK, 11 March 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract [...]
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics Dundee, UK, 11 March 2024: Ubiquigent Limited [...]
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully support continued clinical development of EXN407 [...]
SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the Phase IIa trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase [...]
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for Cell and Gene Therapy Production
Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet Digital™ PCR During Cell and Gene Therapy Production HERCULES, Calif. — February 27, 2024 — Bio-Rad Laboratories, Inc. (NYSE: [...]
Optibrium Launches a Metabolism Prediction Software Platform Tailored to DMPK Scientists
Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery CAMBRIDGE, UK, 27 February 2024 [...]
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients. Investment led by Mercia [...]
Optibrium enables collaborative design in its StarDrop platform
The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking The software promotes collaboration within and across teams [...]